ATE286026T1 - Amid-derivate und deren medizinische verwendung - Google Patents
Amid-derivate und deren medizinische verwendungInfo
- Publication number
- ATE286026T1 ATE286026T1 AT00902925T AT00902925T ATE286026T1 AT E286026 T1 ATE286026 T1 AT E286026T1 AT 00902925 T AT00902925 T AT 00902925T AT 00902925 T AT00902925 T AT 00902925T AT E286026 T1 ATE286026 T1 AT E286026T1
- Authority
- AT
- Austria
- Prior art keywords
- halogen
- alkyl
- hydrogen
- compound
- medical use
- Prior art date
Links
- 150000001408 amides Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- -1 cyano, nitro, amino Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical group [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3336799 | 1999-02-10 | ||
| JP19847399 | 1999-07-13 | ||
| PCT/JP2000/000767 WO2000047558A1 (en) | 1999-02-10 | 2000-02-10 | Amide compounds and medicinal use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE286026T1 true ATE286026T1 (de) | 2005-01-15 |
Family
ID=26372047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00902925T ATE286026T1 (de) | 1999-02-10 | 2000-02-10 | Amid-derivate und deren medizinische verwendung |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7015218B1 (de) |
| EP (1) | EP1176140B1 (de) |
| JP (1) | JP3419395B2 (de) |
| KR (1) | KR100659007B1 (de) |
| CN (1) | CN1230421C (de) |
| AT (1) | ATE286026T1 (de) |
| AU (1) | AU2460600A (de) |
| BR (1) | BR0008173A (de) |
| CA (1) | CA2362381C (de) |
| DE (1) | DE60017115T2 (de) |
| ES (1) | ES2234564T3 (de) |
| HK (1) | HK1046136A1 (de) |
| IL (1) | IL144826A0 (de) |
| MX (1) | MXPA01008142A (de) |
| NZ (1) | NZ514095A (de) |
| WO (1) | WO2000047558A1 (de) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ513639A (en) | 1999-04-15 | 2004-02-27 | Bristol Myers Squibb Co | Cyclic protein tyrosine kinase inhibitors |
| US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| AU780572B2 (en) * | 1999-10-18 | 2005-04-07 | University Of Connecticut, The | Pyrazole derivatives as cannabinoid receptor antagonists |
| MXPA03000923A (es) * | 2000-07-31 | 2003-06-09 | Smithkline Beecham Plc | Compuestos de carboxamida y su uso como antagonistas de un receptor 11cby humano. |
| AU2001277731A1 (en) | 2000-08-09 | 2002-02-18 | Welfide Corporation | Fused bicyclic amide compounds and medicinal use thereof |
| WO2002055100A2 (en) * | 2000-10-20 | 2002-07-18 | Genetics Institute, Llc | Method and composition for inhibition of tumor growth and enhancing an immune response |
| DE10121252A1 (de) * | 2001-04-30 | 2002-11-07 | Christos C Zouboulis | Behandlung der Akne |
| JP2002338537A (ja) * | 2001-05-16 | 2002-11-27 | Mitsubishi Pharma Corp | アミド化合物およびその医薬用途 |
| DE10133665A1 (de) * | 2001-07-11 | 2003-01-30 | Boehringer Ingelheim Pharma | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung |
| FR2828488B1 (fr) * | 2001-08-08 | 2005-06-10 | Oreal | Composition pour la teinture de fibres keratiniques contenant une paraphenylenediamine substituee par un radical diazacycloheptane |
| EP1944304B1 (de) * | 2001-08-13 | 2012-11-28 | E.I. Du Pont De Nemours And Company | Neuartige substituierte 1H-Dihydropyrazole, ihre Zubereitung und Verwendung |
| US7038057B2 (en) | 2001-08-13 | 2006-05-02 | E.I. Du Pont De Nemours And Company | Substituted 1H-dihydropyrazoles, their preparation and use |
| EP1417204B1 (de) | 2001-08-15 | 2006-01-18 | E. I. du Pont de Nemours and Company | Mit heterocyclen ortho-substituierte aryl amide zur bekämpfung wirbelloser schädlinge |
| RU2330839C2 (ru) | 2002-01-11 | 2008-08-10 | Санкио Компани, Лимитед | Производные аминоспиртов или производные фосфорных кислот и фармацевтические композиции, содержащие указанные производные |
| HRP20050092A2 (en) * | 2002-06-29 | 2005-02-28 | Zentaris Gmbh | Arylcarbonylpiperazines and heteroarylcarbonylpiperazines and the use thereof for treating benign and malignant tumour diseases |
| EP1565150A1 (de) * | 2002-11-20 | 2005-08-24 | L'oreal | Verwendung eines pyrazolcarboxamidderivates zur stimulation von keratinischem faserwachstum und/oder zur verhinderung von dessen verlust |
| FR2847160A1 (fr) * | 2002-11-20 | 2004-05-21 | Oreal | Composition capillaire contenant un compose pyrasol-carboxamide, son utilisation pour stimuler la pousse des cheveux et/ou freiner leur chute |
| CN1732155A (zh) * | 2002-12-27 | 2006-02-08 | 三共农业株式会社 | 4-氨基-5-甲基吡唑衍生物及其制备方法 |
| DE10306250A1 (de) * | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US7223788B2 (en) | 2003-02-14 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments |
| ATE482747T1 (de) * | 2003-04-11 | 2010-10-15 | High Point Pharmaceuticals Llc | Neue amide derivate und deren pharmazeutische verwendungen |
| EP1854487A3 (de) * | 2003-04-11 | 2010-09-22 | High Point Pharmaceuticals, LLC | Kombinationspräparate welche einen 11-beta-Hydroxysteroiddehydrogenase Typ-1 Hemmer und einen Agonist des Glucocorticoidrezeptors enthalten |
| GB2401040A (en) * | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
| ES2350837T3 (es) | 2003-05-01 | 2011-01-27 | Bristol-Myers Squibb Company | Compuestos de pirazol-amida sustituidos con arilo útiles como inhibidores de quinasas. |
| WO2004110998A1 (en) | 2003-05-16 | 2004-12-23 | Ambit Biosciences Corporation | Pyrrole compounds and uses thereof |
| DE10325439A1 (de) * | 2003-05-21 | 2004-12-09 | Bayer Cropscience Ag | Iodpyrazolylcarboxanilide |
| TWI355934B (en) | 2004-02-24 | 2012-01-11 | Sankyo Co | Pharmaceutical composition for treatment or prophy |
| EP1568698A1 (de) | 2004-02-27 | 2005-08-31 | Aventis Pharma Deutschland GmbH | Pyrrolderivate als faktor-xa-inhibitoren |
| US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| US8026237B2 (en) * | 2004-07-30 | 2011-09-27 | Exelixis, Inc. | Pyrrole derivatives as pharmaceutical agents |
| GB0421908D0 (en) * | 2004-10-01 | 2004-11-03 | Angeletti P Ist Richerche Bio | New uses |
| BRPI0614141A2 (pt) * | 2005-08-05 | 2016-11-22 | Basf Se | composto, composição fungicida, uso de compostos, método para controlar fungos nocivos fitopatogênicos, e, semente |
| US7406394B2 (en) | 2005-08-22 | 2008-07-29 | Applied Materials, Inc. | Spectra based endpointing for chemical mechanical polishing |
| WO2007052843A1 (ja) * | 2005-11-04 | 2007-05-10 | Takeda Pharmaceutical Company Limited | 複素環アミド化合物およびその用途 |
| US7737149B2 (en) | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
| DK2116530T3 (da) * | 2007-02-26 | 2013-01-28 | Santen Pharmaceutical Co Ltd | Nyt pyrrolderivat, der har en ureidgruppe og en aminobonylgruppe som substituenter |
| US20090023731A1 (en) * | 2007-03-22 | 2009-01-22 | Arete Therapeutics, Inc. | Soluble epoxide hydrolase inhibitors |
| US20090099201A1 (en) * | 2007-05-22 | 2009-04-16 | David Robert Bolin | Diacylglycerol Acyltransferase Inhibitors |
| US8058299B2 (en) * | 2007-05-22 | 2011-11-15 | Via Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
| US8153644B2 (en) | 2007-05-22 | 2012-04-10 | Madrigal Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
| US8115011B2 (en) * | 2007-05-22 | 2012-02-14 | Madrigal Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
| JP5602349B2 (ja) * | 2007-11-20 | 2014-10-08 | 旭化成ファーマ株式会社 | ミゾリビン及び/又はリバビリンの測定方法 |
| BRPI0912245A2 (pt) | 2008-03-05 | 2019-09-24 | Takeda Pharmaceuticals Co | composto, prodroga, medicamento, métodos de suprimir produção de açúcar em um mamífero e para a profilaxia ou o tratamento de diabetes em um mamífero, e, uso do composto |
| WO2009153592A1 (en) * | 2008-06-19 | 2009-12-23 | Astrazeneca Ab | Pyrazole compounds 436 |
| US8211884B2 (en) | 2008-08-06 | 2012-07-03 | Madrigal Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
| GB0815781D0 (en) * | 2008-08-29 | 2008-10-08 | Xention Ltd | Novel potassium channel blockers |
| US8324385B2 (en) | 2008-10-30 | 2012-12-04 | Madrigal Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
| EP2356090B1 (de) * | 2008-11-11 | 2017-07-05 | Novartis AG | Kristalline formen von fingolimod hcl |
| US8211914B2 (en) | 2008-12-17 | 2012-07-03 | Madrigal Pharmaceuticals, Inc. | Inhibitors of diacylglycerol acyltransferase |
| US8946231B2 (en) | 2009-03-23 | 2015-02-03 | Merck Sharp & Dohme Corp. | P2X3, receptor antagonists for treatment of pain |
| EP2236505A1 (de) | 2009-04-03 | 2010-10-06 | Bayer CropScience AG | Acylierte Aminopyridine und - pyridazine als Insektizide |
| US8669259B2 (en) * | 2009-08-26 | 2014-03-11 | Merck Sharp & Dohme Corp. | Heterocyclic amide compounds as protein kinase inhibitors |
| CN102127065B (zh) * | 2010-05-19 | 2014-02-12 | 江苏省农药研究所股份有限公司 | 邻杂环甲酰取代苯胺类化合物及其合成方法和应用 |
| KR20140000695A (ko) | 2010-10-14 | 2014-01-03 | 미쓰비시 타나베 파마 코퍼레이션 | 아미드 유도체 및 그 용도 |
| US9198911B2 (en) | 2010-11-02 | 2015-12-01 | The Trustees Of Columbia University In The City Of New York | Methods for treating hair loss disorders |
| SI2635299T1 (sl) * | 2010-11-02 | 2020-02-28 | The Trustees Of Columbia University In The City Of New York | Postopki za zdravljenje motenj izgube las |
| FR2974576B1 (fr) | 2011-04-29 | 2013-07-19 | Sanofi Aventis | Derives de n-[(1h-pyrazol-1-yl)aryl]-1h-indole ou 1h- indazole-3-carboxamide, leur preparation et leurs applications en therapeutique |
| WO2013020069A1 (en) | 2011-08-03 | 2013-02-07 | Ma Zhongmin | Treatment of type 2 diabetes with fty720 |
| ES2694681T3 (es) * | 2012-03-29 | 2018-12-26 | The Trustees Of Columbia University In The City Of New York | Métodos para tratar trastornos de pérdida capilar |
| AU2013247671A1 (en) * | 2012-04-13 | 2014-10-23 | Mitsubishi Tanabe Pharma Corporation | Amidopyridine derivative, and use thereof |
| US20140179712A1 (en) | 2012-12-21 | 2014-06-26 | Astrazeneca Ab | Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide |
| EP2943197A1 (de) | 2013-01-10 | 2015-11-18 | Grünenthal GmbH | Pyrazolylbasierte carboxamide ii als crac-kanal-hemmer |
| EP2943196A1 (de) | 2013-01-10 | 2015-11-18 | Grünenthal GmbH | Pyrazolylbasierte carboxamide i als crac-kanal-hemmer |
| JP2015096499A (ja) * | 2013-10-11 | 2015-05-21 | 田辺三菱製薬株式会社 | 医薬組成物 |
| WO2015090580A1 (en) * | 2013-12-18 | 2015-06-25 | Grünenthal GmbH | Pyrazolyl-based carboxamides useful as calcium release activated calcium channel (icrac) inhibitors |
| WO2015090579A1 (en) * | 2013-12-18 | 2015-06-25 | Grünenthal GmbH | Pyrazolyl-based carboxamides iv |
| LT3113772T (lt) | 2014-03-07 | 2020-12-28 | Biocryst Pharmaceuticals, Inc. | Trifluormetilo pakeistieji pirazolai kaip žmogaus plazmos kalikreino inhibitoriai |
| WO2015197187A1 (en) | 2014-06-24 | 2015-12-30 | Grünenthal GmbH | Pyrazolyl-based carboxamides v |
| WO2015197188A1 (en) * | 2014-06-24 | 2015-12-30 | Grünenthal GmbH | Pyrazolyl-based carboxamides as crac inhibitors |
| CN104829592B (zh) * | 2015-05-22 | 2017-03-15 | 河南科技大学第一附属医院 | 4‑哌啶基‑1h‑吡咯‑3‑甲酰胺类化合物盐酸盐的合成方法 |
| WO2019067530A1 (en) * | 2017-09-26 | 2019-04-04 | The Broad Institute, Inc. | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY INTESTINAL DISEASE |
| JP7296408B2 (ja) * | 2018-06-18 | 2023-06-22 | ヤンセン ファーマシューティカ エヌ.ベー. | Malt1阻害剤としてのピラゾール誘導体 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4046775A (en) | 1973-04-11 | 1977-09-06 | Sterling Drug Inc. | 4,5-Dihalopyrrole-2-carboxamides |
| US4134987A (en) * | 1976-01-14 | 1979-01-16 | Huppatz John L | Compounds and compositions |
| ZA887773B (en) | 1987-10-26 | 1989-07-26 | Immunex Corp | Interleukin-7 |
| FR2662692B1 (fr) | 1990-05-30 | 1995-04-28 | Novapharme | Derives heterocycliques doues d'activite anticonvulsivante, procede de preparation et composition pharmaceutique. |
| US5368854A (en) * | 1992-08-20 | 1994-11-29 | Schering Corporation | Use of IL-10 to treat inflammatory bowel disease |
| NZ255757A (en) | 1992-08-20 | 1997-07-27 | Schering Corp | Compositions and methods for the use of il-4 and/or il-10 and antibodies against these cytokines |
| WO1994004180A2 (en) | 1992-08-20 | 1994-03-03 | Schering Corporation | Novel uses of il-4 and/or il-10, and antibodies against the same |
| ZA95960B (en) | 1994-03-14 | 1995-10-10 | Genetics Inst | Use of interleukin-12 antagonists in the treatment of autoimmune diseases |
| US6020121A (en) | 1995-09-29 | 2000-02-01 | Microcide Pharmaceuticals, Inc. | Inhibitors of regulatory pathways |
| GB9608435D0 (en) * | 1996-04-24 | 1996-06-26 | Celltech Therapeutics Ltd | Chemical compounds |
| EP1068187A1 (de) * | 1998-04-08 | 2001-01-17 | Abbott Laboratories | Pyrazole als inhibitoren der cytokinproduktion |
-
2000
- 2000-02-10 KR KR1020017010127A patent/KR100659007B1/ko not_active Expired - Fee Related
- 2000-02-10 ES ES00902925T patent/ES2234564T3/es not_active Expired - Lifetime
- 2000-02-10 US US09/913,260 patent/US7015218B1/en not_active Expired - Fee Related
- 2000-02-10 JP JP2000598479A patent/JP3419395B2/ja not_active Expired - Fee Related
- 2000-02-10 IL IL14482600A patent/IL144826A0/xx unknown
- 2000-02-10 MX MXPA01008142A patent/MXPA01008142A/es unknown
- 2000-02-10 CN CNB008061084A patent/CN1230421C/zh not_active Expired - Fee Related
- 2000-02-10 HK HK02107626.5A patent/HK1046136A1/zh unknown
- 2000-02-10 AU AU24606/00A patent/AU2460600A/en not_active Abandoned
- 2000-02-10 CA CA002362381A patent/CA2362381C/en not_active Expired - Fee Related
- 2000-02-10 WO PCT/JP2000/000767 patent/WO2000047558A1/ja not_active Ceased
- 2000-02-10 DE DE60017115T patent/DE60017115T2/de not_active Expired - Lifetime
- 2000-02-10 AT AT00902925T patent/ATE286026T1/de not_active IP Right Cessation
- 2000-02-10 BR BR0008173-6A patent/BR0008173A/pt not_active IP Right Cessation
- 2000-02-10 EP EP00902925A patent/EP1176140B1/de not_active Expired - Lifetime
- 2000-02-10 NZ NZ514095A patent/NZ514095A/xx not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1176140A1 (de) | 2002-01-30 |
| IL144826A0 (en) | 2002-06-30 |
| KR100659007B1 (ko) | 2007-02-28 |
| AU2460600A (en) | 2000-08-29 |
| CA2362381A1 (en) | 2000-08-17 |
| HK1046136A1 (zh) | 2002-12-27 |
| WO2000047558A1 (en) | 2000-08-17 |
| CN1346348A (zh) | 2002-04-24 |
| JP3419395B2 (ja) | 2003-06-23 |
| EP1176140A4 (de) | 2002-07-31 |
| KR20010102040A (ko) | 2001-11-15 |
| CA2362381C (en) | 2009-12-22 |
| US7015218B1 (en) | 2006-03-21 |
| DE60017115D1 (de) | 2005-02-03 |
| NZ514095A (en) | 2001-09-28 |
| BR0008173A (pt) | 2002-10-22 |
| CN1230421C (zh) | 2005-12-07 |
| ES2234564T3 (es) | 2005-07-01 |
| DE60017115T2 (de) | 2005-12-08 |
| EP1176140B1 (de) | 2004-12-29 |
| MXPA01008142A (es) | 2003-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60017115D1 (de) | Amid-derivate und deren medizinische verwendung | |
| DE69829875D1 (de) | Piperazin-verbindungen und ihre medizinische verwendung | |
| NO970892L (no) | Isoksazolderivater | |
| ATE334975T1 (de) | Sulfonamidderivate, ihre herstellung und verwendung | |
| DE69418704D1 (de) | Anthranilsäure derivate | |
| ATE232531T1 (de) | Heterobizyklische derivate | |
| BR9103433A (pt) | Derivados de 4-benzil-isoxazol | |
| EE03139B1 (et) | Piperasiiniderivaadid, nende kasutamine ja farmatseutiline kompositsioon | |
| BR0207846A (pt) | Derivados heterocìclicos para o tratamento de câncer e outras doenças proliferativas | |
| AU7517400A (en) | N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent | |
| DK0565377T3 (da) | Terapeutiske midler til behandling af Parkinsons sygdom | |
| ES2126075T3 (es) | Derivados biciclicos nitrogenados como inhibidores de la propil-endopeptidasa. | |
| EP0779074A4 (de) | Wirkstoff zum schutz für organ oder gewebe | |
| PT801062E (pt) | Derivados de pirimidina | |
| DE69332366D1 (de) | Arylsubstituierte heterocyclische Verbindungen | |
| DE69329184D1 (de) | Alkylsubstituierte heterocyclische Verbindungen | |
| ATE137759T1 (de) | S'-adenosyl-methionin-decarboxylase-inhibitoren | |
| DE69832614D1 (de) | Benzopyranderivate zur behandlung von perihperer gefässerkrankung | |
| DE69523819D1 (de) | Quinolin-Derivate und diese enthaltende pharmazeutische Zusammensetzungen | |
| ATE336496T1 (de) | Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen | |
| RU94038051A (ru) | Гетероциклические производные, способ их получения, фармацевтическая композиция и способ лечения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |